[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100624838":3},{"organization":4,"armGroups":7,"interventions":27,"overallOfficials":39,"centralContacts":43,"locations":48,"responsibleParty":178,"collaborators":33,"id":180,"slug":181,"hasResults":182,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":33,"eligibilityCriteria":186,"healthyVolunteers":182,"sex":187,"minAge":188,"maxAge":33,"enrollmentInfo":189,"targetDuration":33,"studyType":192,"phases":193,"briefSummary":195,"conditions":196,"keywords":198,"overallStatus":51,"whyStopped":33,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":210},{"fullName":5,"class":6},"BeOne Medicines","INDUSTRY",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"Phase 1a: Monotherapy Dose Escalation","EXPERIMENTAL","Participants will receive increasing doses of BG-C0979 as monotherapy.",[13],"Drug: BG-C0979",{"label":15,"type":10,"description":16,"interventionNames":17},"Phase 1a: Monotherapy Safety Expansion","Participants will receive BG-C0979 as monotherapy. Selected dose levels that have been determined to be safe in Phase 1a dose escalation will be further evaluated in safety expansion.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Phase 1b, Part A: Monotherapy Dose Optimization and Dose Expansion","Participants will receive BG-C0979 as monotherapy in a dose optimization and dose expansion phase at different dose levels of recommended doses for expansion (RDFEs) identified in Phase 1a.",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Phase 1b, Part B: Combination Therapy Expansion","Participants will receive BG-C0979 in combination with tislelizumab in select tumor types.",[13,26],"Drug: Tislelizumab",[28,34],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"DRUG","BG-C0979","Administered by intravenous infusion.",[9,15,19,23],null,{"type":29,"name":35,"description":31,"armGroupLabels":36,"otherNames":37},"Tislelizumab",[23],[38],"BGB-A317",[40],{"name":41,"affiliation":5,"role":42},"Study Director","STUDY_DIRECTOR",[44],{"name":41,"role":45,"phone":46,"phoneExt":33,"email":47},"CONTACT","8778285568","clinicaltrials@beonemed.com",[49,63,73,85,94,104,114,126,136,146,157,163,172],{"facility":50,"status":51,"city":52,"state":53,"zip":54,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":33},"John Theurer Cancer Center Hackensack University Medical Center","RECRUITING","Hackensack","New Jersey","07601","United States","US",{"type":58,"coordinates":59},"Point",[60,61],-74.04347,40.88593,{"lat":61,"lon":60},{"facility":64,"status":51,"city":65,"state":66,"zip":67,"country":55,"countryCode":56,"cosmosGeoPoint":68,"geoPoint":72,"contacts":33},"Next Oncology San Antonio","San Antonio","Texas","78229",{"type":58,"coordinates":69},[70,71],-98.49363,29.42412,{"lat":71,"lon":70},{"facility":74,"status":51,"city":75,"state":76,"zip":77,"country":78,"countryCode":79,"cosmosGeoPoint":80,"geoPoint":84,"contacts":33},"Northern Beaches Hospital","Frenchs Forest","New South Wales","NSW 2086","Australia","AU",{"type":58,"coordinates":81},[82,83],151.22322,-33.74821,{"lat":83,"lon":82},{"facility":86,"status":51,"city":87,"state":76,"zip":88,"country":78,"countryCode":79,"cosmosGeoPoint":89,"geoPoint":93,"contacts":33},"Liverpool Hospital","Liverpool","NSW 2170",{"type":58,"coordinates":90},[91,92],150.92588,-33.91938,{"lat":92,"lon":91},{"facility":95,"status":51,"city":96,"state":97,"zip":98,"country":78,"countryCode":79,"cosmosGeoPoint":99,"geoPoint":103,"contacts":33},"Icon Cancer Centre South Brisbane","South Brisbane","Queensland","QLD 4101",{"type":58,"coordinates":100},[101,102],153.02049,-27.48034,{"lat":102,"lon":101},{"facility":105,"status":51,"city":106,"state":107,"zip":108,"country":78,"countryCode":79,"cosmosGeoPoint":109,"geoPoint":113,"contacts":33},"Cabrini Hospital Malvern","Malvern","Victoria","VIC 3144",{"type":58,"coordinates":110},[111,112],145.02811,-37.86259,{"lat":112,"lon":111},{"facility":115,"status":51,"city":116,"state":117,"zip":118,"country":119,"countryCode":120,"cosmosGeoPoint":121,"geoPoint":125,"contacts":33},"Second Affiliated Hospital of Army Medical University (Xinqiao Hospital)","Chongqing","Chongqing Municipality","400037","China","CN",{"type":58,"coordinates":122},[123,124],106.55771,29.56026,{"lat":124,"lon":123},{"facility":127,"status":51,"city":128,"state":129,"zip":130,"country":119,"countryCode":120,"cosmosGeoPoint":131,"geoPoint":135,"contacts":33},"Mengchao Hepatobiliary Hospital of Fujian Medical University","Fuzhou","Fujian","350028",{"type":58,"coordinates":132},[133,134],119.30611,26.06139,{"lat":134,"lon":133},{"facility":137,"status":51,"city":138,"state":139,"zip":140,"country":119,"countryCode":120,"cosmosGeoPoint":141,"geoPoint":145,"contacts":33},"Yichang Central Peoples Hospital","Yichang","Hubei","443003",{"type":58,"coordinates":142},[143,144],111.28472,30.71444,{"lat":144,"lon":143},{"facility":147,"status":51,"city":148,"state":33,"zip":149,"country":150,"countryCode":151,"cosmosGeoPoint":152,"geoPoint":156,"contacts":33},"Hospital Universitario Vall Dhebron","Barcelona","08035","Spain","ES",{"type":58,"coordinates":153},[154,155],2.15899,41.38879,{"lat":155,"lon":154},{"facility":158,"status":51,"city":148,"state":33,"zip":159,"country":150,"countryCode":151,"cosmosGeoPoint":160,"geoPoint":162,"contacts":33},"Hospital Clinic de Barcelona","08036",{"type":58,"coordinates":161},[154,155],{"lat":155,"lon":154},{"facility":164,"status":51,"city":165,"state":33,"zip":166,"country":150,"countryCode":151,"cosmosGeoPoint":167,"geoPoint":171,"contacts":33},"Hospital Universitario Fundacion Jimenez Diaz","Madrid","28040",{"type":58,"coordinates":168},[169,170],-3.70256,40.4165,{"lat":170,"lon":169},{"facility":173,"status":51,"city":165,"state":33,"zip":174,"country":150,"countryCode":151,"cosmosGeoPoint":175,"geoPoint":177,"contacts":33},"Next Oncology Madrid","28223",{"type":58,"coordinates":176},[169,170],{"lat":170,"lon":169},{"type":179,"investigatorFullName":33,"investigatorTitle":33,"investigatorAffiliation":33,"oldNameTitle":33,"oldOrganization":33},"SPONSOR","100624838","phase-1-a-first-in-human-study-of-bg-c0979-in-adults-with-advanced-solid-tumors-100624838",false,"NCT07414836","A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors","A Multicenter, Open-Label, Phase 1a\u002Fb First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BG-C0979 in Patients With Selected Advanced Solid Tumors","Inclusion Criteria:\n\n* Phase 1a (Monotherapy Dose Escalation and Safety Expansion): Participants with histologically or cytologically confirmed advanced, metastatic, and unresectable solid tumors who have previously received standard systemic therapy or for whom treatment is not available or not tolerated, or determined not appropriate based on investigator's judgment.\n* Phase 1b Part A (Monotherapy Dose Optimization and Expansion): Participants with histologically or cytologically confirmed advanced, metastatic, and unresectable solid tumors who have previously received standard systemic therapy or for whom treatment is not available or not tolerated, or determined not appropriate based on investigator's judgment.\n* Phase 1b Part B (Combination Therapy Expansion): Participants with histologically or cytologically confirmed metastatic or unresectable advanced solid tumors who have not received any prior systemic treatment for advanced or metastatic disease.\n* Participants must have ≥ 1 measurable lesion as assessed by RECIST v1.1.\n* Participants must have a stable Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.\n* Participants must have adequate organ function.\n\nExclusion Criteria:\n\n* Prior treatment with any ADAM9-targeted antibody-drug conjugates (ADCs) or ADCs containing TOPO1 inhibitor as payload.\n* Active leptomeningeal disease or uncontrolled, untreated brain metastasis.\n\nNote: Other protocol defined Inclusion\u002FExclusion criteria may apply.","ALL","18 Years",{"count":190,"type":191},84,"ESTIMATED","INTERVENTIONAL",[194],"PHASE1","The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of BG-C0979 monotherapy or in combination with tislelizumab in participants with selected advanced solid tumors. The study will consist of Phase 1a (Dose Escalation and Safety Expansion) and Phase 1b (Dose Expansion).",[197],"Advanced Solid Tumor",[199,200],"ADAM9 (disintegrin and metalloproteinase 9)","antibody-drug conjugate","2026-06-17",{"date":203,"type":204},"2026-06-18","ACTUAL",{"date":206,"type":204},"2026-04-13",{"date":208,"type":191},"2029-04-30",{"name":5,"class":6},13]